Arnd Christ
Director of Finance/CFO chez IMMATICS N.V.
Fortune : 2 M $ au 31/03/2024
Profil
Arnd Christ is the founder of Cf Port GmbH.
He currently holds the position of Chief Financial Officer at Immatics Biotechnologies GmbH and Immatics NV.
Previously, he served as Finance Director at Avery Dennison Corp., Hoechst AG, and Avery Dennison GmbH.
He also held the role of Chief Financial Officer at MediGene AG, Vivoryon Therapeutics NV, NovImmune SA, Proteros biostructures GmbH, and EleGene AG.
Additionally, he was the Chief Financial Officer at InflaRx NV until 2020.
Mr. Christ has also served as a Member-Supervisory Board at Immunocore Holdings Plc.
He obtained an MBA from Boston University and Wuerzburg Schweinfurt University of Applied Sciences.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMATICS N.V.
0,16% | 31/01/2024 | 169 907 ( 0,16% ) | 2 M $ | 31/03/2024 |
Postes actifs de Arnd Christ
| Sociétés | Poste | Début |
|---|---|---|
| IMMATICS N.V. | Director of Finance/CFO | 01/10/2020 |
| Cf Port GmbH | Founder | - |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Director of Finance/CFO | 01/01/2020 |
Anciens postes connus de Arnd Christ
| Sociétés | Poste | Fin |
|---|---|---|
| INFLARX N.V. | Director of Finance/CFO | 01/10/2020 |
Proteros biostructures GmbH
 Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Director of Finance/CFO | 01/01/2014 |
| MEDIGENE AG | Director of Finance/CFO | 19/09/2012 |
| NOVIMMUNE SA | Director of Finance/CFO | 01/01/2010 |
| VIVORYON THERAPEUTICS N.V. | Director of Finance/CFO | 01/01/2007 |
Formation de Arnd Christ
| Boston University | Masters Business Admin |
| Wuerzburg Schweinfurt University of Applied Sciences | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| AVERY DENNISON CORPORATION | Process Industries |
| MEDIGENE AG | Health Technology |
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| INFLARX N.V. | Health Technology |
| IMMATICS N.V. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Entreprise privées | 7 |
|---|---|
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Novimmune SA
 Novimmune SA Medical/Nursing ServicesHealth Services Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland. | Health Services |
Proteros biostructures GmbH
Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Health Services |
| EleGene AG | |
| Cf Port GmbH | |
| Avery Dennison GmbH |
